The effects of transdermal and oral oestrogen replacement therapy on colorectal cancer risk in postmenopausal women.
The effects of transdermal and oral oestrogen replacement therapy on colorectal cancer risk in postmenopausal women.
复制标题
DOI：
10.1038/sj.bjc.6601438
复制
发表时间：
2004-01-12
影响因子：
8.8
通讯作者：
中科院分区：
文献类型：
--
作者：
本研究的目的是检查口服和经皮雌激素替代疗法对结直肠癌风险的影响。对一项旨在研究激素替代疗法（HRT）对结直肠癌影响的巢式病例对照研究的数据进行了分析。1992年至1998年中期（N=1197）诊断的结直肠癌的新病例，确定使用萨斯喀彻温省癌症机构癌症登记。50岁以上的妇女，符合萨斯喀彻温省处方药计划的覆盖范围，被纳入研究。采用发病密度抽样，每例病例有4名年龄匹配的对照。门诊处方药计划数据库用于确定雌激素处方。根据经皮（TDE）和口服（OE）雌激素使用史对女性进行分类。条件Logistic回归用于估计比值比（OR）和95%置信区间（CI）。与从未使用HRT的妇女相比，TDE使用<3年和<13年与结直肠癌的OR值分别为0.69（95% CI：0.43-1.10）和0.33（95% CI：0.12-0.95），OE使用分别为0.90（95% CI：0.73-1.01）和0.75（95% CI：0.60-0.93）。与口服HRT相比，TDE降低结直肠癌风险的幅度可能更大。
The aim of this study was to examine the effects of oral and transdermal oestrogen replacement therapy on the risk of colorectal cancer. Data from a nested case–control study, designed to investigate the effect of hormone replacement therapy (HRT) on colorectal cancer were analysed. New cases of colorectal cancer, diagnosed between 1992 and mid-1998 (N=1197), were identified using the Saskatchewan Cancer Agency cancer registry. Women ⩾50 years of age, eligible for coverage by the Saskatchewan Prescription Drug Plan, were included in the study. Four controls per case were age matched to cases, using incidence density sampling. The outpatient prescription drug plan database was used to ascertain oestrogen prescriptions. Women were classified according to history of transdermal (TDE) and oral (OE) oestrogen use. Conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). Compared with women who had never used HRT, ORs for <3 and ⩾3 years of TDE use and colorectal cancer were 0.69 (95% CI: 0.43–1.10) and 0.33 (95% CI: 0.12–0.95), and for OE use were 0.90 (95% CI: 0.73–1.01) and 0.75 (95% CI: 0.60–0.93), respectively. The risk reduction for colorectal cancer with TDE may be greater in magnitude than that which has been reported for oral HRT.
登录
查看更多内容
影响因子：
6.7
作者：
Jewelewicz, R
通讯作者：
Jewelewicz, R
影响因子：
4.9
作者：
Gruber, DM;Huber, JC
通讯作者：
Huber, JC
DOI：
10.1097/00042192-200205000-00006
发表时间：
2002-05-01
影响因子：
2.7
作者：
Santen, RJ;Pinkerton, JV;Klein, KO
通讯作者：
Klein, KO
影响因子：
2.3
作者：
JACOBS, EJ;WHITE, E;WEISS, NS
通讯作者：
WEISS, NS
影响因子：
120.7
作者：
Grady, D;Herrington, D;Wenger, N
通讯作者：
Wenger, N